{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:23:45Z","timestamp":1790645025281,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.seizure.2013.09.009","type":"journal-article","created":{"date-parts":[[2013,9,23]],"date-time":"2013-09-23T11:48:33Z","timestamp":1379936913000},"page":"36-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Efficacy of verapamil as an adjunctive treatment in children with drug-resistant epilepsy: A pilot study"],"prefix":"10.1016","volume":"23","author":[{"given":"Francesco","family":"Nicita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Spalice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Papetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Nikanorova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Iannetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2013.09.009_bib0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1528-1167.2007.00992.x","article-title":"Refractory epilepsy: clinical overview","volume":"48","author":"French","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2013.09.009_bib0010","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S1474-4422(08)70108-X","article-title":"Intractable epilepsy: management and therapeutic alternatives","volume":"7","author":"Schuele","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.seizure.2013.09.009_bib0015","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMra1004418","article-title":"Drug-resistant epilepsy","volume":"365","author":"Kwan","year":"2011","journal-title":"N Eng J Med"},{"key":"10.1016\/j.seizure.2013.09.009_bib0020","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1528-1167.2007.01357.x","article-title":"Mechanisms of drug resistance in status epilepticus","volume":"48","author":"Loscher","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2013.09.009_bib0025","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.0013-9580.2005.31904.x","article-title":"Potential role of drug transporters in the pathogenesis of medically intractable epilepsy","volume":"46","author":"Kwan","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2013.09.009_bib0030","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1111\/j.1528-1167.2011.03140.x","article-title":"In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein","volume":"52","author":"Zhang","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2013.09.009_bib0035","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.addr.2011.12.003","article-title":"The transport of antiepileptic drugs by P-glycoprotein","volume":"64","author":"Zhang","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.seizure.2013.09.009_bib0040","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.eplepsyres.2009.02.014","article-title":"Addition of verapamil in the treatment of severe myoclonic epilepsy in infancy","volume":"85","author":"Iannetti","year":"2009","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2013.09.009_bib0045","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1345\/aph.1E068","article-title":"Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy","volume":"38","author":"Summers","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.seizure.2013.09.009_bib0050","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/j.1528-1167.2005.59204.x","article-title":"Calcium-channel blocker verapamil administration in prolonged and refractory status epilepticus","volume":"46","author":"Iannetti","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2013.09.009_bib0055","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.yebeh.2010.01.166","article-title":"Verapamil attenuates the malignant treatment course in recurrent status epilepticus","volume":"17","author":"Schmitt","year":"2010","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2013.09.009_bib0060","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1111\/j.1468-1331.2011.03513.x","article-title":"Termination of refractory focal status epilepticus by the P-glycoprotein inhibitor verapamil","volume":"18","author":"Pirker","year":"2011","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.seizure.2013.09.009_bib0065","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1528-1167.2010.02522.x","article-title":"Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005\u20132009","volume":"51","author":"Berg","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2013.09.009_bib0070","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.nbd.2006.06.014","article-title":"The multiple transporter hypothesis of drug resistance in epilepsy: proof-of-principle in a rat model of temporal lobe epilepsy","volume":"24","author":"Brandt","year":"2006","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.seizure.2013.09.009_bib0075","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1124\/jpet.107.121178","article-title":"Region-specific overexpression of P-glycoprotein at the blood-brain barrier affects brain uptake of phenytoin in epileptic rats","volume":"322","author":"Van Vliet","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.seizure.2013.09.009_bib0080","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1528-1167.2010.02886.x","article-title":"Add-on treatment with verapamil in pharmacoresistant canine epilepsy","volume":"52","author":"Jambroszyk","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2013.09.009_bib0085","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrn1728","article-title":"Drug resistance in brain diseases and the role of drug efflux transporters","volume":"6","author":"Loscher","year":"2005","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.seizure.2013.09.009_bib0090","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/brain\/awh437","article-title":"Multidrug resistance in epilepsy: rats with drug-resistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures","volume":"128","author":"Volk","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.seizure.2013.09.009_bib0095","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/brain\/awf002","article-title":"Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy","volume":"125","author":"Sisodiya","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.seizure.2013.09.009_bib0100","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1093\/brain\/aws147","article-title":"Neuropathology of the blood-brain barrier and pharmaco-resistance in human epilepsy","volume":"135","author":"Liu","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.seizure.2013.09.009_bib0105","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.eplepsyres.2008.10.010","article-title":"Over-expression of P-glycoprotein in the canine brain following spontaneous status epilepticus","volume":"83","author":"Pekcec","year":"2009","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2013.09.009_bib0110","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(13)70109-1","article-title":"P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study","author":"Feldmann","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.seizure.2013.09.009_bib0115","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1111\/j.1528-1167.2007.01116.x","article-title":"Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[11C] verapamil","volume":"48","author":"Langer","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2013.09.009_bib0120","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1177\/0883073810365737","article-title":"Genotype-phenotype correlations in a group of 15 SCN1A-mutated Italian patients with GEFS+spectrum (seizures plus, classical and borderline severe myoclonic epilepsy of infancy)","volume":"25","author":"Nicita","year":"2010","journal-title":"J Child Neurol"},{"key":"10.1016\/j.seizure.2013.09.009_bib0125","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1111\/j.1528-1167.2006.00643.x","article-title":"Nonfunctional SCN1A is common in severe myoclonic epilepsy of infancy","volume":"47","author":"Ohmori","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2013.09.009_bib0130","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1535-7597.2004.42010.x","article-title":"Inherited channelopathies associated with epilepsy","volume":"4","author":"George","year":"2004","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.seizure.2013.09.009_bib0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1472-8206.2007.00548.x","article-title":"Drugs and their molecular targets: an updated overview","volume":"1","author":"Landry","year":"2008","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.seizure.2013.09.009_bib0140","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.seizure.2010.05.004","article-title":"ABC1 C3435T polymorphisms and the risk of resistance to antiepileptic drugs in epilepsy: a systematic review and meta-analysis","volume":"19","author":"Haerian","year":"2010","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2013.09.009_bib0145","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(13)70128-5","article-title":"P-glycoprotein expression and antiepileptic drug resistance","author":"French","year":"2013","journal-title":"Lancet Neurol"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131113002562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131113002562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:43:33Z","timestamp":1761011013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131113002562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S1059131113002562"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2013.09.009","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of verapamil as an adjunctive treatment in children with drug-resistant epilepsy: A pilot study","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2013.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}